<DOC>
	<DOC>NCT02132143</DOC>
	<brief_summary>The purpose of this study compares chemoradiation and sequential chemoradiation about Lung adenocarcinoma patients with postoperative in pN2 and then determines which therapeutic method is better for the patients.</brief_summary>
	<brief_title>Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Clinical diagnosis of Lung adenocarcinoma Postoperative staging pN2 period Voluntary participation and informed consent Age ≥ 18 years old, male or female, within six months of weight loss of less than 10%, can tolerate radiotherapy performance status( PS) score 02. Hemoglobin ≥ 80 g / L, white blood cell ≥ 4 × 109 / L, platelets ≥ 100 × 109 / L. Liver function: alanine aminotransferase (ALAT), aspartate transaminase (ASAT) &lt;upper limit of normal (ULN) of 1.5 times, bilirubin &lt;1.5 × ULN. Renal function: serum creatinine &lt;1.5 × ULN. Compliance, and can be regular followup, voluntary compliance with study requirements Do not meet the inclusion criteria There is evidence of distant metastases Suffered from other malignancies in five years Within the past January subjects received other drug trials Having serious allergies or idiosyncratic persons, such as you can not use folic acid, dexamethasone, vitamin B12 patients Severe lung or heart disease, a history Refuses or is unable to sign informed consent to participate in trials The abuse of drugs or alcohol addicts. Patients with difficult to control bacterial, viral, fungal infections Having a personality or mental disorders, without civil capacity or restricted civil capacity. Being pregnant or lactating women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Lung adenocarcinoma</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Sequential chemoradiotherapy</keyword>
	<keyword>Progression-free survival</keyword>
</DOC>